ロード中...
Obinutuzumab for relapsed or refractory indolent non-Hodgkin’s lymphomas
The use of anti-CD20 monoclonal antibodies (mAbs), such as rituximab, in CD20-positive B-cell malignancies has dramatically improved the outcome of chronic lymphoid leukemia and non-Hodgkin’s lymphomas (NHL). However, the occurrence of relapse and development of rituximab-refractory disease highligh...
保存先:
| 出版年: | Ther Adv Hematol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4802503/ https://ncbi.nlm.nih.gov/pubmed/27054024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715622613 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|